Same sparkle, different story: how lab-grown diamonds are transforming the market 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
World game at war: why some European nations have threatened a World Cup boycott 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
(4) - EconoTimes)
BURLINGTON, Mass., May 03, 2018 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to seven new employees for an aggregate of 38,300 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an effective date of May 1, 2018. The stock options have an exercise price of $25.22 per share and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. The stock options are subject to the terms and conditions of the Company's 2013 Equity Incentive Plan and a stock option agreement pursuant to which the stock option was granted.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. For the past two years, Flexion has been named one of the Best Places to Work by the Boston Business Journal, and Flexion was also recognized as a Top Place to Work in Massachusetts by The Boston Globe in 2017.
Corporate Contact:
Scott Young
Vice President, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]
